The father of the dominant theory of Alzheimer’s disease told another eminent researcher he is “causing harm” by criticizing ...

In addition, Eisai must conduct a post-authorization safety study, including setting up a patient registry for the European Union. Now each European country must set its own rules for access and ...

A new report from the Alzheimer's Association indicates people feel that the earlier they know about a diagnosis, the sooner they can seek treatment options.

SEATTLE — There's new hope for people in the early stages of Alzheimer's disease. A new medication called donanemab appears ...

UW has begun treating patients with donanemab, a new Alzheimer’s medication that may slow cognitive decline in people with ...

The second U.S. drug shown to slow the progression of early Alzheimer's has arrived in Seattle-area clinics. One of the first ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of science, technology, and medicine news ...

Conference after conference, Roche scientists running the ongoing Brain Shuttle AD trial of trontinemab are dispensing ...

A team of scientists, including researchers from University College London (UCL), has discovered key differences in how four ...

A team of scientists including UCL researchers has tested four anti-amyloid Alzheimer's therapeutics to find out how the drugs bind to toxic amyloid beta protein to tackle the disease.

Buoyed by the breakthrough technologies and methodologies that have enabled earlier intervention, Alzheimer’s drug developers ...

A team of scientists including UCL researchers has tested four anti-amyloid Alzheimer's therapeutics to find out how the ...